![]() Tessera and Pioneering Medicinesan initiative that brings together complementary technologies from Flagship Pioneering's portfolio of companieswill advance the technology through preclinical development and prepare it for first-in-human proof of concept studies. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and. This includes the ability to make true corrections of specific mutations, such as the F508-del mutation, which drives roughly 70% of CF cases, as well as other nonsense mutations, and to introduce a functional full-length copy of the CFTR gene at its endogenous locus. The agreement involves multiple Gene Writers in Tessera's portfolio of candidates and applies them to cystic fibrosis. We hope our collaboration leads to treatments and cures for cystic fibrosis. The Cystic Fibrosis Foundation's extensive network of scientists, companies, and clinicians knowledgeable about cystic fibrosis will help accelerate screening and development of our cystic fibrosis-targeting Gene Writers. We're excited to work with the Cystic Fibrosis Foundation, the world's leader in supporting breakthrough technologies for cystic fibrosis, said Geoffrey von Maltzahn, Ph.D, Co-Founder and CEO of Tessera, and General Partner at Flagship Pioneering. Furthermore, current treatments are ineffective for about 10% of individuals living with cystic fibrosis. While major advances have been made over the past decade that have led to more therapeutic options for individuals living with cystic fibrosis, a curative approach is still lacking. It affects approximately 70 thousand people globally. Cystic fibrosis is an inherited genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that cause persistent and worsening lung congestion and infections that limit a person's ability to breathe. This transaction is expected to close during Q1 of 2017. Gene Writers make precise single nucleotide changes, small insertions and deletions, and can replace entire genes in a programmable way to correct the genetic code driving disease. CAMBRIDGE, Mass., November 03, 2021-Tessera Therapeutics announces a treatment-focused collaboration with the Cystic Fibrosis Foundation using its Gene Writing technology. AstraZeneca announced today that it has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |